PetMed Express

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PetMed Express reports Q1 2023 earnings, anticipates growth from PetCareRx acquisition

PetMed Express faced sales decline, but the acquisition of PetCareRx and strong new customer growth provide optimism for future profitability. Financial stability, operational focus, and strategic partnerships position the company for long-term success.

PetMed Express reports Q3 sales dip but gains new customers

PetMed Express navigated challenges with a 3% decrease in YoY sales but gained 9% more net new customers. The company's focus on pet health expertise and expanding offerings positions it for future growth.
Despite advertising spending increases, PetMed maintains a strong balance sheet with over $102 million in unrestricted cash. Management's confidence in future prospects and innovative strategies bode well for the company's growth trajectory.

PetMed Express reports sales decline, eyes growth from acquisitions

PetMed Express focused on pet wellness, recent acquisitions, and strategic investments in telemedicine and pet insurance.
Despite sales decline in fiscal year 2023, the company aims for growth from the PetCareRx acquisition in 2024.
Challenges in over-the-counter medication sales and a net loss in Q4 were offset by a strong cash position and strategic focus on growth.

PetMed Express reports record revenue growth and expands pet insurance

PetMed Express (PETS) demonstrated strong financial performance in Q1 2024, with record-setting revenue growth and a focus on sustainable long-term growth.
The company's strategic initiatives, including the integration of the PetCareRx acquisition and expansion into the pet insurance market, position it for future success.
While facing challenges in a competitive market, PetMed Express has opportunities to solidify its market leadership in pet wellness and healthcare through customer-centric strategies.

PetMed Express reports Q2 growth, shifts focus to tech investments

PetMed Express (PETS) demonstrated solid financial performance in Q2 2024 with revenue growth and operational enhancements. While facing challenges in customer retention and market conditions, the company is strategically investing in technology and growth initiatives. With a focus on long-term sustainability and innovation, PetMed Express aims to drive growth and shareholder value in the pet health sector.

PetMed Express reports strong sales growth amidst accounting challenges

PetMed Express shows resilience in sales growth despite accounting challenges.
The company's focus on transparency and customer programs is a key strength.
Challenges include the need for a financial restatement and maintaining investor confidence.
Opportunities lie in strengthening internal controls and driving growth through acquisitions.

PetMed Express reports sales growth, invests in tech for future

PetMed Express (PETS) reported positive sales growth in Q4 2024 driven by the PetCareRx acquisition, despite a net loss due to acquisition-related expenses.
The company's customer-centric focus, strategic investments in technology, and strong leadership team additions position it well for future growth.
Challenges include managing expenses post-acquisition and navigating competitive pressures in the pet medications market, while opportunities exist in market expansion and operational enhancements.

PetMed Express (PETS) reports Q1 challenges but sees early improvements

PetMed Express (PETS) navigated a transition quarter with a focus on growth and profitability. Despite a sales decline and margin decrease, early signs of improvement were observed. The company emphasized optimizing cost structure, enhancing customer growth strategies, and implementing technology improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PetMed Express, Inc. provides markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, and generic substitutes. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Fiscal 2024 3Q Revenue of $65.3 million , an 11% increase compared to last year including PetCareRx results. AutoShip & Save and PetPlus Membership, 52% of total revenue, up from 42% at the same time last year. Strong balance sheet with $49.4 million of cash The Company is now current in all of its SEC filings

PetMeds® Announces Fiscal 2024 Third Quarter Financial Results and Completion of Financial Restatement

C3.ai

Enovix Corporation

If you're after a list of information technology (IT) stocks short sellers are targeting, then one should study this article carefully. IT stocks have been facing some headwinds recently, with valuations that appeared stretched even as the broader markets have been volatile.

3 IT Stocks on Short Sellers' Radar: Is a Tech Reckoning Imminent

AMC Entertainment

Fisker Inc

Lucid Group

LivePerson

MicroVision

New York Community Bancorp

Investor enthusiasm for risk continues to increase as the stock market notches up fresh highs. Hence, amidst the bullishness, it's an opportune time to offload penny stocks to sell and optimize your portfolio.

7 Penny Stocks to Sell in March Before They Crash & Burn

AGNC Investment

FAT Brands

Redwood Trust

Vodafone Group

While Most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the most significant public companies, especially the technology giants, trade over $1000 per share, while many are in the low to mid-hundreds. It's hard to get decent share count leverage at those steep prices.

5 Sizzling Stocks Under $10 That Also Pay Ultra Yield Dividends

Chewy

Freshpet

Petco Health and Wellness

As popular as pets are, pet stocks have been in the toilet and can't seem to get out. The landscape is littered (no pun intended) with broken stocks like online e-commerce retailer Chewy Inc. NYSE: CHWY shares down 56%, PetMed Express Inc. NASDAQ: PETS is down 71.7%, and Petco Health and Wellness Inc. NASDAQ: WOOF down 75% in the last year.

Here's The One Pet Stock That's Not in the Doghouse

B2Gold

Oversold stocks are the equivalent of Wall Street's clearance sale. Many times, stores have too much inventory of certain products that are holding up valuable real estate.

3 Oversold Stocks Presenting a Value Opportunity

The giveaway comes as PetMeds® partners with Hill's Pet Nutrition to make Science Diet available through petmeds.com, starting March 1 The giveaway comes as PetMeds® partners with Hill's Pet Nutrition to make Science Diet available through petmeds.com, starting March 1

PetMeds® to Give Away Free Pet Food for a Year to Three Lucky Pet Owners and $1,000 in PetMeds® Credits to Three Local Animal Shelters

Birkenstock Holding Plc

1-800-FLOWERS.COM

A few hours before writing this, I got an email letting me know packages had arrived at my door. It's a recurring theme at our house and probably yours too.

3 Hidden-Gem E-commerce Stocks Ready to Ride a Massive Market Wave

DELRAY BEACH, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS), received on February 13, 2024, a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC.

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express, Inc. (PETS) Q3 2024 Earnings Call Transcript

Company to Restate Certain Previously Issued Financial Statements Due to Correction of Errors in Accounting for Tax-Related Entries; Filing of Form 10-Q to be Delayed Company to Restate Certain Previously Issued Financial Statements Due to Correction of Errors in Accounting for Tax-Related Entries; Filing of Form 10-Q to be Delayed

PetMeds® Announces Selected Preliminary Third Quarter Financial Results

PennantPark Investment

Ship Finance

The company operates in various maritime, shipping, and offshore sectors, including: Oil transportation Dry bulk shipments Chemical transportation Oil products transportation Container transportation Car transportation Drilling rigs As of December 31, 2022, the company owned: Ten crude oil tankers 15 dry bulk carriers 32 container vessels Three car carriers One jack-up drilling rig, One ultra-deepwater drilling unit Two chemical tankers Six oil product tankers It primarily operates in Bermuda, Cyprus, Liberia, Norway, Singapore, the United Kingdom, and the Marshall Islands.

5 Small-Cap Stocks That Pay Huge Ultra-Yield Dividends

DELRAY BEACH, Fla., Jan. 29, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (Nasdaq: PETS) (the “Company”), Your Trusted Pet Health ExpertTM will hold a conference call on Thursday, February 8, 2024 at 4:30pm Eastern time to discuss its financial results for the fiscal third quarter ended December 31, 2023. Financial results will be issued in a press release prior to the call.

PetMed Express, Inc. Sets Fiscal Third Quarter 2024 Earnings Call

DELRAY BEACH, Fla. , Jan. 8, 2024 /PRNewswire/ -- PetMed Express, Inc. ("PetMeds®") (NASDAQ: PETS), Your Trusted Pet Health Expert™, announces the appointment of Leslie C.

PetMeds® Announces new Chairman of the Board

StealthGas

Vizsla Silver Corp

Penny stocks can be your best friend but also your worst enemy. Although individual pennies often provide lucrative returns, a diversified penny stock portfolio tends to underperform the S&P 500.

3 Penny Stocks That Are About to Get Absolutely Crushed

Zoetis

Pet stocks are an exciting way to diversify your portfolio. These companies ride high on the tailwinds of the pet care industry, which took many analysts by surprise.

3 Promising Stocks to Buy in the Booming Pet Tech Industry

As employees continue to return to work at offices, the ping of missing their pets at home has become more pronounced. A PetMeds® survey of 2,000 pet parents uncovered new data that supports the bond between pets and their humans.

Both Pets and Pet Parents Feel the Strain of Separation Anxiety When Apart, According to a New Survey from PetMeds®

Big 5 Sporting Goods

V.F.

Vanguard Dividend Appreciation ETF

In response to macroeconomic challenges, numerous companies are reducing expenses to safeguard their earnings, which can sometimes involve reducing or eliminating dividends. This article highlights three dividend stocks whose weak Dividend Safety Grades were highlighted well before cuts that could have been avoided. Economic oscillation, declining earnings, inflation, and rising interest rates have pressured profits and companies' ability to maintain dividends.

Dividend Stocks: Cuts You Could Have Avoided

Veterinary professor and industry luminary, Dr. Lori Teller, will lead the Board as it oversees company initiatives and fosters collaboration within the veterinary community DELRAY BEACH, Fla. , Nov. 13, 2023 /PRNewswire/ -- PetMed Express, Inc. (PetMeds®, NASDAQ: PETS), Your Trusted Pet Health Expert™, today announced the creation of its Veterinarian Advisory Board to help the company improve outcomes for pets and pet parents across the United States.

PetMeds® Announces the Formation of Veterinarian Advisory Board

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your PetMed investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities la.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of PetMed Express, Inc. (PETS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS) investors concerning the Company's possible violations of federal securities laws. On October 30, 2023, PetMed released its financial results for the second quarter of 2023, reporting net sales of $71 million, missing estimates by $5 million. Additionally, the Company disclosed that it “made a decision to suspend the quarterly div.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of PetMed Express, Inc. (PETS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On October 30, 2023, PetMed released its financial results for the second quarter of 2023, reporting net sales of $71 million, missing estimates by $5 million. Additionally,.

The Law Offices of Frank R. Cruz Announces Investigation of PetMed Express, Inc. (PETS) on Behalf of Investors

Investors in PetMed Express Inc.'s stock are suffering their worst day in 23 years, after the pet medication and supplies company reported disappointing quarterly results and said it would suspend its dividend to save cash.

PetMed's stock plunges to 19-year low as dividend yield to drop from 19% to zero

PetMed Express (NASDAQ: PETS ) stock is falling on Tuesday after the pet pharmacy announced earnings for its fiscal second quarter of 2023. That bad news for PETS stock starts with the company's flat earnings per share for the quarter.

Why Is PetMed Express (PETS) Stock Down 28% Today?

PetMed (PETS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.18. This compares to earnings of $0.13 per share a year ago.

News for PetMed Express Stock (PETS)